Moors & Cabot, Inc. Sorrento Therapeutics, Inc. Transaction History

Moors & Cabot, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.74 - $1.83 $33,115 - $81,892	44,750 Added 380.85%	56,500 $50,000
Q4 2022 Feb 06, 2023	SELL	$0.74 - $1.83 $34,595 - $85,552	-46,750 Reduced 79.91%	11,750 $10,000
Q3 2022 Nov 07, 2022	SELL	$1.51 - $2.88 $4,530 - $8,640	-3,000 Reduced 4.88%	58,500 $92,000
Q2 2022 Aug 08, 2022	SELL	$1.24 - $2.33 $1,240 - $2,330	-1,000 Reduced 1.6%	61,500 $124,000
Q1 2022 May 13, 2022	BUY	$2.0 - $4.9 $101,500 - $248,675	50,750 Added 431.91%	62,500 $146,000
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.23 $61,612 - $95,797	-13,250 Reduced 53.0%	11,750 $55,000
Q3 2021 Nov 05, 2021	BUY	$7.41 - $10.99 $185,250 - $274,750	25,000 New	25,000 $26,000
Q4 2020 Feb 11, 2021	SELL	$5.76 - $11.95 $101,664 - $210,917	-17,650 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$6.17 - $18.82 $108,900 - $332,173	17,650 New	17,650 $197,000

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.